GC Biopharma announced on the 23rd that it plans to supply a total of 5.94 million doses of its flu vaccine "GCFLU," having won the bid from Thailand's state-owned pharmaceutical company Government Pharmaceutical Organization (GPO) and the Disease Control Department (DDC), including the private market.
Thailand, geographically spanning both the Southern and Northern Hemispheres, is one of the markets that requires a continuous supply of flu vaccines year-round according to the World Health Organization (WHO) vaccination guidelines.
The company noted that it has secured bids from GPO for both the Northern and Southern Hemisphere and the national bid from the Thai government, marking the largest quantity ever. The company first entered the Thai flu vaccine market in 2014 and has expanded its export volumes every year. The supply volume to the private market in Thailand increased by 112% compared to last year. The company expects that this bid win will push its cumulative order quantity past 15 million doses.
Lee Woo-jin, head of global business at GC Biopharma, said, "Thanks to administrative support such as the Ministry of Food and Drug Safety's assistance with vaccine export and the shortening of national shipping approval timelines, export contracts are being actively concluded." He added, "We will do our best to promote the excellence of GCFLU based on the proven product quality in the international procurement market over a long time."
"GCFLU" is exported to 63 countries. GC Biopharma is the largest supplier of flu vaccines under the WHO and has surpassed a cumulative production of 300 million doses.